The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of molecular therapy on radioactive iodine uptake in patients with oncogene-driven metastatic differentiated thyroid cancer.
 
Adeline T Yang
No Relationships to Disclose
 
Blair Segers
No Relationships to Disclose
 
Olivia Caradonio
No Relationships to Disclose
 
Supriya Behl
No Relationships to Disclose
 
Yimei Li
No Relationships to Disclose
 
Hongming Zhuang
No Relationships to Disclose
 
Lisa States
No Relationships to Disclose
 
Priya Mahajan
No Relationships to Disclose
 
Tyler Garrett Ketterl
Consulting or Advisory Role - Cardinal Health; Fennec Pharma
 
Steven G. Waguespack
Honoraria - Bayer
Consulting or Advisory Role - Bayer
 
Amber Isaza
No Relationships to Disclose
 
Lindsay Sisko
No Relationships to Disclose
 
Aime Franco
No Relationships to Disclose
 
Andrew J. Bauer
Consulting or Advisory Role - Egetis Therapeutics; IBSA
Research Funding - Egetis Therapeutics (Inst)
Travel, Accommodations, Expenses - Bayer Austrailia
 
Theodore Willis Laetsch
Stock and Other Ownership Interests - Advanced Microbubbles
Honoraria - Cook Children's Hospital
Consulting or Advisory Role - AI Therapeutics; Aptitude Health; Bayer; GentiBio; ITM Oncologics; Jazz Pharmaceuticals; Jumo Health; Massive Bio; Medscape; Menarini; Novartis; Pyramid Biosciences; Targeted Oncology; Treeline Biosciences
Research Funding - Advanced Accelerator Applications/Novartis; Bayer (Inst); BioAtla; Bristol-Myers Squibb; Lilly; Pfizer (Inst); Roche; Roche/Genentech; Taiho Oncology; Turning Point Therapeutics (Inst)